Oncology

A new Phase III clinical trial has revealed that combining nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) improves progression-free survival in patients with Stage III or IV classic Hodgkin’s lymphoma compared to the standard brentuximab vedotin with AVD (BV+AVD).

A recent study has spotlighted the regulatory divide between the US Food and Drug Administration’s (FDA) Accelerated Approval (AA) pathway and the European Medicines Agency’s (EMA) Conditional Marketing Authorization (CMA) process, showing stark differences in their cancer drug approvals.

Overtreatment of prostate cancer persists among men with limited life expectancy within the Veterans Affairs (VA) health system.

A genetic variant, the BIM deletion polymorphism (BDP), has been identified by researchers to significantly enhance leukemia stem and progenitor cells’ survival, making them resistant to common targeted therapies.

A powerful link between health insurance status and racial and ethnic disparities in advanced cancer diagnoses has been identified in a recently published study.

Prognostic value of specific visceral protein ratios in patients with colon cancer can offer healthcare professionals a novel approach to estimating progression-free survival (PFS) and overall survival (OS) in affected patients.

A recent study sheds light on how estrogen signaling affects immune response in breast cancer, potentially opening pathways for combined anti-estrogen and immunotherapy approaches.

Nearly half of patients with metastatic melanoma treated with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab have survived cancer-free, underscoring the impact of immunotherapy in advanced melanoma.